Contipro
Manufactures high-purity hyaluronic acid and nanotechnology-based biomedical materials, enabling vertical integration for pharmaceutical and tissue engineering applications with over 2 billion CZK in annual revenue.
- CEO / Founder
- Vladimir Velebny
- Team Size
- 201-500
- Stage
- Active
- Total Funding
- $2.2M
- Latest Round
- Grant
- Key Investors
- CzechInvest
Technology & Products
Key Products
Hyaluronic acid and its derivatives for pharmaceutical and cosmetic industries, including anti-aging cosmetic raw materials, pharmaceutical-grade sodium hyaluronate, and nutritional supplements (Geloren Active). Proprietary 4SPIN technology for nanofiber scaffolds.
Technological Advantage
Claimed: Vertical integration and nanotechnology expansion. Verified: Sustained revenue over 2 billion CZK and successful launch of 4SPIN nanofiber device for tissue engineering.
Differentiation
Value Proposition
Reduces supply chain risk and ensures pharmaceutical-grade purity through vertical integration of hyaluronic acid production, while providing proprietary 4SPIN nanotechnology for high-precision tissue engineering and drug delivery.
How They Differentiate
Full vertical integration as a primary manufacturer of pharmaceutical-grade hyaluronic acid provides a significant cost and purity advantage for bio-ink production; proprietary 4SPIN technology enables precise, automated electrospinning of nanofiber scaffolds for tissue engineering applications.
Market & Competition
Target Customers
Pharmaceutical companies, cosmetic manufacturers, veterinary medicine providers, tissue engineering applications
Industry Verticals
Pharmaceutical; Veterinary; Cosmetics; Biomedical devices; Tissue engineering
Competitors
Lifecore, Fidia Farma, Bloomage Biotechnology
Growth & Milestones
Growth Metrics
Revenue exceeded 2 billion CZK for consecutive years as of 2022.
Major Milestones
1991: Company founded; 2000-11: Bonharen launched; 2004-01: Entry into human pharmaceutical market; 2009-06: Hyiodine launched; 2012-10: Entry into nanotechnology field with 4SPIN device; 2021-09: New analytical center opened; 2022-04: Revenue exceeded 2 billion CZK; new Geloren production line launched
Notable Customers
Main cosmetic transnationals, pharmaceutical industries.